Rim1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RIM1 in NeuroWiki maps to the presynaptic active-zone gene RIMS1 (Regulating Synaptic Membrane Exocytosis 1). RIMS1 encodes a large scaffold protein that helps dock and prime synaptic vesicles for calcium-triggered fusion at chemical synapses.[1][2] Through direct binding to Rab3 family GTPases, calcium-channel complexes, and vesicle-priming machinery, RIM1 is a central determinant of release probability and short-term plasticity.[2:1][3]
RIM1 is most strongly expressed in neuronal populations that demand fast and reliable transmission, including cortical and hippocampal glutamatergic neurons and cerebellar circuits.[1:1][4] In neurodegeneration research, RIM1 is typically interpreted as a vulnerability node for early synaptic failure rather than a primary aggregation protein.[4:1][5]
| Property | Value |
|---|---|
| Preferred symbol | RIMS1 (RIM1) |
| Full name | Regulating Synaptic Membrane Exocytosis 1 |
| Chromosome | 6q13 (reported locus for human RIMS1) |
| NCBI Gene | RIMS1 Gene |
| Ensembl | ENSG00000067325 |
| Encoded protein | RIM1 Protein |
| Related pathway pages | Synaptic Vesicle Trafficking, Synaptic Dysfunction in Alzheimer's |
RIM1 is an active-zone organizer that performs three tightly coupled jobs.[1:2][2:2]
This architecture makes RIM1 a functional bridge between structural active-zone proteins and dynamic release regulation.[1:3][2:5]
Direct Mendelian neurodegenerative syndromes driven by RIMS1 are uncommon, but synaptic-pathway studies repeatedly implicate RIM1-containing release modules in disease-relevant network dysfunction.[4:2][5:1]
Alzheimer's disease features early presynaptic and postsynaptic failure. RIM-dependent active-zone integrity is part of this presynaptic compartment, and reduced synapse-associated proteins correlate with cognitive decline.[4:3][5:2] RIM1 should therefore be interpreted as a mechanistic component of the broader synaptic loss axis rather than an isolated biomarker.[4:4]
In Parkinson's disease, defects in vesicle handling, SNARE cycling, and alpha-synuclein stress converge at presynaptic terminals.[8][9] Because RIM1 calibrates vesicle availability and release probability, altered RIM1 complexes may amplify dopaminergic synaptic fragility when other presynaptic stressors are present.[8:1][9:1]
In amyotrophic lateral sclerosis, progressive synaptic disconnection and excitability imbalance involve presynaptic molecular systems as disease advances.[10] RIM1 is not a canonical ALS risk gene, but it is biologically upstream of transmitter-release efficiency in corticospinal and spinal circuits that undergo degeneration.[10:1]
RIM1 is better suited to network and synapse-state modeling than to direct gene-targeted therapy today.[2:6][5:3] Practical use cases include:
The study of Rim1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gundelfinger ED, Kessels MM, Qualmann B. Temporal and spatial coordination of exocytosis and endocytosis at synapses. Cell Mol Life Sci. 2003. ↩︎ ↩︎ ↩︎ ↩︎
Sudhof TC. The presynaptic active zone. Annu Rev Neurosci. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kaeser PS, Deng L, Wang Y, Dulubova I, Liu X, Rizo J, Sudhof TC. RIM proteins tether Ca2+ channels to presynaptic active zones via a direct PDZ-domain interaction. Cell. 2011. ↩︎ ↩︎ ↩︎
de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Deng L, Kaeser PS, Xu W, Sudhof TC. RIM proteins activate vesicle priming by reversing autoinhibitory homodimerization of Munc13. Neuron. 2011. ↩︎ ↩︎
Castillo PE. Presynaptic LTP and LTD of excitatory and inhibitory synapses. Cold Spring Harb Perspect Biol. 2012. ↩︎
Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron. 2013. ↩︎ ↩︎ ↩︎
Bridi JC, Hirth F. Mechanisms of alpha-synuclein induced synaptopathy in Parkinson's disease. Front Neurosci. 2018. ↩︎ ↩︎
Fogarty MJ. Driven to decay: excitability and synaptic abnormalities in amyotrophic lateral sclerosis. Brain Res Bull. 2019. ↩︎ ↩︎